Lu Junjie, Hu Desheng, Ma Chen, Shuai Bo
Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol. 2022 Jun 14;13:938447. doi: 10.3389/fphar.2022.938447. eCollection 2022.
Osteoporosis (OP) is known as a silent disease in which the loss of bone mass and bone density does not cause obvious symptoms, resulting in insufficient treatment and preventive measures. The losses of bone mass and bone density become more severe over time and an only small percentage of patients are diagnosed when OP-related fractures occur. The high disability and mortality rates of OP-related fractures cause great psychological and physical damage and impose a heavy economic burden on individuals and society. Therefore, early intervention and treatment must be emphasized to achieve the overall goal of reducing the fracture risk. Anti-OP drugs are currently divided into three classes: antiresorptive agents, anabolic agents, and drugs with other mechanisms. In this review, research progress related to common anti-OP drugs in these three classes as well as targeted therapies is summarized to help researchers and clinicians understand their mechanisms of action and to promote pharmacological research and novel drug development.
骨质疏松症（OP）是一种隐匿性疾病，骨量和骨密度的丧失不会引起明显症状，导致治疗和预防措施不足。随着时间的推移，骨量和骨密度的丧失会变得更加严重，只有一小部分患者在发生与OP相关的骨折时才被诊断出来。与OP相关的骨折的高致残率和死亡率会造成巨大的心理和身体伤害，并给个人和社会带来沉重的经济负担。因此，必须强调早期干预和治疗，以实现降低骨折风险的总体目标。目前抗OP药物分为三类：抗吸收剂、促合成剂和具有其他作用机制的药物。在这篇综述中，总结了这三类常见抗OP药物以及靶向治疗的研究进展，以帮助研究人员和临床医生了解其作用机制，并促进药理学研究和新药开发。
